Hospital
Three Crosses Regional Hospital LLC
Three Crosses Regional Hospital LLC was paid $6.55M by Medicaid between Feb 2021 and Dec 2024, across 143 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoTHREE CROSSES REGIONAL HOSPITAL LLC
LAS CRUCES, NM 88001
LAS CRUCES, NM 88001
33aNPI1760020044assigned 12/17/2019
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.55M
24GClaims137,230
24DCodes billed143
24AFirst – last monthFeb 2021 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Mexico
Rank by total paid#20 of 24
Median peer was paid$20.13M
This provider vs. median0.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 2,992 | $174K | |
| 2022 | 23,470 | $1.24M | |
| 2023 | 46,893 | $2.18M | |
| 2024incomplete | 63,875 | $2.96M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 7,797 | 7,477 | $1.22M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 5,005 | 4,763 | $1.16M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 2,664 | 2,540 | $866K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.0% | 1,033 | 1,001 | $265K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.5% | 2,967 | 2,815 | $230K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.8% | 3,619 | 3,381 | $184K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.7% | 1,535 | 1,486 | $176K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.5% | 3,096 | 2,773 | $163K |
| 71045 | Radiologic examination, chest; single view | 2.4% | 3,044 | 2,880 | $158K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 1,048 | 1,006 | $134K |
| G0378 | Hospital observation service, per hour | 1.9% | 461 | 331 | $127K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.9% | 1,255 | 1,224 | $125K |
131 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 2,393 | $108K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 2,352 | $94K |
| 76830 | Ultrasound, transvaginal | 1.3% | 814 | $87K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 1,269 | $76K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.1% | 691 | $73K |
| 80053 | Comprehensive metabolic panel | 1.1% | 8,847 | $73K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 1.0% | 184 | $67K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 380 | $55K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,159 | $54K |
| J3490 | Unclassified drugs | <1% | 9,717 | $53K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,035 | $53K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 1,481 | $52K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,839 | $51K |
| 72110 | <1% | 592 | $48K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 168 | $45K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,040 | $41K |
| 72170 | <1% | 469 | $34K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,142 | $34K |
| 93229 | <1% | 277 | $34K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 408 | $34K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 308 | $29K |
| 93458 | <1% | 26 | $27K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,598 | $26K |
| 84484 | <1% | 2,391 | $24K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 341 | $22K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 149 | $22K |
| 72100 | <1% | 273 | $21K | |
| 96376 | <1% | 382 | $20K | |
| 87430 | <1% | 1,225 | $19K | |
| 80320 | <1% | 398 | $18K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 5,599 | $18K |
| 83880 | <1% | 717 | $17K | |
| 83690 | <1% | 2,944 | $16K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 112 | $15K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,023 | $15K |
| 85610 | <1% | 3,618 | $14K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,823 | $13K |
| 81025 | <1% | 1,624 | $12K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 640 | $11K |
| 73562 | <1% | 138 | $11K | |
| 83735 | <1% | 2,280 | $11K | |
| 83605 | <1% | 998 | $9K | |
| 81001 | <1% | 3,083 | $8K | |
| 93970 | <1% | 57 | $7K | |
| 86850 | <1% | 460 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,054 | $6K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 276 | $6K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 12 | $6K |
| 73030 | <1% | 76 | $6K | |
| 73610 | <1% | 74 | $6K | |
| 80061 | Lipid panel | <1% | 455 | $6K |
| 85027 | <1% | 1,039 | $5K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 37 | $5K |
| 73130 | <1% | 86 | $5K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 628 | $5K |
| 76641 | <1% | 46 | $5K | |
| 31720 | <1% | 31 | $5K | |
| Q0181 | Unspecified oral dosage form, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for a iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 482 | $5K |
| 85730 | <1% | 1,005 | $4K | |
| 86141 | <1% | 380 | $4K | |
| 73630 | <1% | 74 | $4K | |
| 64483 | <1% | 12 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 658 | $4K |
| 82150 | <1% | 797 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,802 | $4K |
| 86900 | <1% | 334 | $4K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $4K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,108 | $3K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 17 | $3K |
| 70498 | <1% | 12 | $3K | |
| 85379 | <1% | 395 | $3K | |
| 84702 | <1% | 207 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,136 | $3K |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 13 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,620 | $2K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 393 | $2K |
| 74022 | <1% | 27 | $2K | |
| 81003 | <1% | 1,054 | $2K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 13 | $2K |
| C1769 | Guide wire | <1% | 128 | $2K |
| A9270 | Non-covered item or service | <1% | 698 | $1K |
| 73700 | <1% | 14 | $1K | |
| 72050 | <1% | 17 | $1K | |
| 82948 | <1% | 280 | $1K | |
| 84439 | <1% | 136 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,120 | $1K |
| 87040 | <1% | 88 | $1K | |
| 72040 | <1% | 12 | $972.71 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 86 | $955.01 |
| 74018 | <1% | 14 | $929.10 | |
| 97161 | <1% | 50 | $926.98 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 641 | $854.38 |
| 73090 | <1% | 15 | $852.68 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 29 | $837.52 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 31 | $808.77 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 68 | $753.98 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 12 | $743.59 |
| 84703 | <1% | 84 | $612.48 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 319 | $600.36 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12 | $465.87 |
| 85652 | <1% | 201 | $434.62 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 15 | $432.33 |
| 0167U | <1% | 176 | $431.42 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 244 | $420.91 |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | <1% | 14 | $409.13 |
| 94760 | <1% | 16 | $401.45 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 194 | $392.44 |
| 87081 | <1% | 70 | $358.28 | |
| J1815 | Injection, insulin, per 5 units | <1% | 12 | $356.87 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 290 | $351.91 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 34 | $342.74 |
| 96367 | <1% | 13 | $337.05 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 55 | $327.65 |
| 84146 | <1% | 13 | $307.06 | |
| 83001 | <1% | 14 | $275.92 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 14 | $275.75 |
| 83002 | <1% | 12 | $252.92 | |
| 84100 | <1% | 91 | $248.95 | |
| 86756 | <1% | 12 | $200.72 | |
| 97116 | <1% | 32 | $194.24 | |
| 80143 | <1% | 12 | $188.72 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 33 | $161.13 |
| 86803 | <1% | 12 | $143.73 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 96 | $138.88 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 103 | $134.50 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 44 | $119.69 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 42 | $106.89 |
| 76942 | <1% | 24 | $84.05 | |
| 82550 | <1% | 15 | $79.88 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 108 | $54.35 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 12 | $23.27 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHUNT, RICHARD (COO)
| Provider | Location | Paid |
|---|---|---|
| Three Crosses Regional Hospital LLC | Las Cruces, NM | $3.22M |
| Biotech X-Ray, INC. | Oshkosh, WI | $6K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.